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An integrative machine learning approach for prediction
of toxicity-related drug safety
Artem Lysenko1 , Alok Sharma1,2, Keith A Boroevich1 , Tatsuhiko Tsunoda1,3,4
Recent trends in drug development have been marked by di-
minishing returns caused by the escalating costs and falling rates
of new drug approval. Unacceptable drug toxicity is a substantial
cause of drug failure during clinical trials and the leading cause
of drug withdraws after release to the market. Computational
methods capable of predicting these failures can reduce the
waste of resources and time devoted to the investigation of
compounds that ultimately fail. We propose an original machine
learning method that leverages identity of drug targets and off-
targets, functional impact score computed from Gene Ontology
annotations, and biological network data to predict drug toxicity.
We demonstrate that our method (TargeTox) can distinguish
potentially idiosyncratically toxic drugs from safe drugs and is
also suitable for speculative evaluation of different target sets to
support the design of optimal low-toxicity combinations.
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Introduction
The last decade has seen an escalation of drug development costs,
and at the same time, the rate at which new successful drugs are
released has actually decreased (1). One striking example of this
trendwas put forward by (2), who observed that during the period of
2004–2014, both the funding and number of drug candidates trialed
in the United States increased substantially, but the number of new
drugs approved declined by more than 25% compared with the
previous decade. Unacceptably high toxicity is a major contributing
cause of drug failure and accounts for about one-ﬁfth of clinical
trial failures (3) and two-thirds of worldwide post-launch with-
drawals (4). One strategy to reduce these costs and improve the
efﬁciency of the drug development is to augment laboratory and
clinical testing with computational analysis (5), and the development
of accurate methods to predict toxicity is pivotal to this goal (6).
Earlier methods for computational pre-screening focused pri-
marily on chemical features of potential compounds. The ﬁrst
approaches were frequently based on rule sets (7) with scores
awarded to compounds for not failing particular criteria of “drug-
likeness”. From the pharmacokinetic perspective, it was proposed
to characterize compounds according to absorption, distribution,
metabolism, and excretion criteria (ADME) (8). Further develop-
ments have led to reﬁnements of simple rule-based methods into
more granular qualitative measures, such as quantitative estimate
for drug-likeness (QED) (9), which uses a desirability function to
compute an optimal score acrossmultiple chemistry-based criteria.
Importantly, most of these efforts were not speciﬁcally intended
only to identify likely toxicity, but to also optimize over a range of
relevant properties that can impact efﬁcacy, bioavailability, and
pharmacokinetics.
A recent evaluation of current methods was performed by (10).
Their work has shown that chemistry-based scoring and rule-based
systems have only very modest power to predict clinical trial failures.
These methods could not accurately predict clinical trial failure due
to drug toxicity if taken in isolation and not combinedwith additional
features. One possible explanation is that these schemes, like Lip-
inski’s Rule of 5 (11), are now routinely used to screen drugs (12), and
compounds at clinical trial stage are likely to have already passed
such screening. Another part of the explanation could be that these
rules do not strongly apply to a very large subset (estimated at
50–80% of all drugs) of “metabolite-like” compounds that can mimic
naturally occurring metabolites and behave in a similar way (13).
Lastly, toxicity-related responses are mostly mediated by drug–
protein interactions (14), which may not necessarily have a clear
correspondence to molecular structure features.
Given the complex nature of the drug toxicity prediction prob-
lem, the chemistry-led approaches outlined above are just one of
the many possible ways to consider it, and other studies have
explored a wide variety of alternative strategies. Several proposed
methods have used various semantic similarity (15) and correlation
measures, such as known side-effect proﬁles (16, 17) to predict
speciﬁc side-effect labels. An alternative perspective was de-
veloped by (18), which used predictive binding to a small number of
already known toxicity-related proteins as an indicator of risk. Yet
another set of strategies rely on leveraging gene expression (19, 20)
and metabolomics proﬁle similarities (21). Although all of these
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works have undoubtedly greatly contributed to our understanding
of the patterns and mechanisms of toxic side effects, not all of
these approaches can be used during drug the development
process because large amounts of in vivo, human-speciﬁc data can
only be safely collected once the risks of the candidate drug are
sufﬁciently understood.
Another complication arises when attempting to integrate or
fairly compare approaches because, often, the scope or prediction
goals of different methods are not readily comparable. Frequently
specialized methods are developed for particular classes of
compounds (22) or speciﬁc, carefully deﬁned scenarios (23, 24).
Although most methods measure their success in terms of their
ability to predict all possible types of side effects (i.e., from rela-
tively benign to highly dangerous), others (10, 25) consider drug
toxicity in terms of drug trail failures or withdrawals from the
market—a criteria most similar to the one used in this study. Clearly
“drug rejection” criteria are not directly comparable with the “side
effect prediction” criteria, as in the former case, most dangerous
side effects are prioritized and “unsafe” category assignment is
indirectly affected by factors such as the overall severity and
frequency of toxic responses and ability to effectively manage
those risks. Although both (10) and (25) used comparable criteria,
the latter made extensive use of drug annotation (phenotypic in-
dications and all known adverse reactions). Such data can only be
collected once the drug is in use for some time and is not available
for new compounds, such as novel candidate drugs from the
ClinicalTrials.gov database used in this study.
Drug toxicity is commonly classiﬁed into two subtypes: Type A or
intrinsic toxicity, which is dose dependent and related to the
primary pharmacological target of the drug, and Type B or idio-
syncratic toxicity (IT), which is unpredictable, occurs at frequencies
of less than 1 in 5,000 cases (26), is not dose dependent, and is
associated with off-target effects (27). Although decisions to
withdraw a drug from the market can be made for a variety of
reasons, unacceptable IT is believed to be the main reason (28, 29,
30, 31). Given that IT is very rare, it can be unnoticeable in smaller
test populations used for clinical trials and is often not detectable
in animal models (27). Our analysis indicated that current leading
methods developed for clinical trial success prediction and drug-
likeness do not perform as well in the case of drugs withdrawn from
the market (Fig S1). This may indicate that a different perspective or
drug properties are needed to speciﬁcally capture those effects.
However, we would like to emphasize that data used to develop
these tools and their goals were not optimized for prediction of
drug withdrawals from the market, and the result reported here is
by no means representative of the performance of these tools in
their intended contexts.
Motivated by the importance of drug–protein interactions in drug
toxicity mechanisms (14) and the increasing prominence of target-
based drug development, in this study, we explore the feasibility of
developing a computational target-driven drug toxicity prediction
method (TargeTox). Themethod uses information about all proteins
that can bind a drug (both intended pharmacological targets and
off-targets) in combination with machine learning to identify po-
tentially toxic compounds. Importantly, drugs can have both type A
and type B toxicity risks at the same time, and therefore, a com-
bination of these factors can lead to the conclusion that particular
drug is unsafe. At present, no relevant databases provide structured
and comprehensive information about type A and type B toxicity
risks; however, it is generally believed that type A toxicity is pre-
dominantly discovered during clinical trials and type B during the
monitoring and reporting stage after release to the market (27). For
these reasons, when designing a training dataset, we aimed to
include examples for both cases, although in our downstream
analysis, we place particular emphasis on conﬁrming performance
for IT cases. Although we aim to predict toxicity risk of both types,
current implementation is not designed to directly identify which
type is prevalent for speciﬁc cases.
One particular challenge in the incorporation of drug-binding
protein data is the sparse nature of the dataset, where each drug
will only bind a relatively small set of all possible proteins and this
number will greatly differ between drugs. At the same time, given
that the set of conﬁrmed toxic drugs satisfying our criteria is small,
large numbers of bound proteins and most interactions will occur
only once in the entire dataset. To address this, we propose to
leverage a guilt-by-association principle in combination with the
biological network context of these proteins. Because it was pre-
viously reported that target proximity in the network corresponds
to the similarity of drug side effects (32), we hypothesized that
severe toxicity-related responses could be localized to particular
regions of the biological network. Here, the network is represented
by a distance matrix of all constituent proteins. Our analysis has
shown that both simpler and more sophisticated network distance
measures can be used with this approach; although based on our
evaluations, diffusion state distance (DSD) (33) was chosen as the
marginally better performing metric. The position of each drug-
speciﬁc set of bound proteins is approximately encoded by dis-
tances to a small number of reference proteins. This interpretation
of the data allows all observations to be meaningfully used, in-
cluding cases where single instances of drug-binding proteins are
found in training or evaluation datasets. Although concepts of
biological network diffusion have been explored in other contexts,
for example, as in (34), the distinguishing and novel feature of our
approach is the direct use of a machine learning classiﬁer to “map
out” areas of the network during the training process, which means
other covariates can also be taken into account in conjunction with
network-based location data. At the same time, this method can
also reduce dimensionality and convert data from sparse to dense
representation.
Results
Drug-binding proteins tend to be non-uniformly distributed in
the network
Information for all drug-binding proteins in our reference set was
acquired from the DrugBank and ChEMBL databases. Although
there was a substantial number of drugs with a single target (Fig 1),
most drugs interacted with more than one protein. The number of
bound proteins was also smaller than the number of drugs, and
about 47% of all these proteins were found in both toxic and safe
subsets. To explore the overall distribution of drug-binding pro-
teins in the context of the human interactome they were combined
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with a protein association network from the STRING database,
which was transformed into a DSDmatrix to do this analysis. Overall
DSD distribution for all proteins in the main connected component
of the network was largely consistent with what was previously
reported by (33) for the yeast protein–protein interaction network
(Fig 2A). The generated distribution had a relatively smooth central
part with a long right tail. To visually explore possible location
patterns of bound proteins, we mapped the complete DSD distance
matrix into two dimensions (Fig 2B) using the t-distributed sto-
chastic neighbor embedding (t-SNE) algorithm (35). Although a
minority of bound proteins appeared to be dispersed throughout
the network, most tended to be co-located in a few distinctive
groups. On average, bound proteins of the same drug tended to be
signiﬁcantly closer together than random samples of the same size,
although there was no difference between average distances of
toxic and safe drug–interacting protein sets (Fig 3A) and the same
pattern was observed when only a subset of drugs withdrawn from
the market was considered (Fig 3B). The overall proximity of the
proteins binding the same drug suggested a possibility that these
sets may be represented more compactly by network locations to
reduce the sparseness and dimensionality of the data while
minimizing the loss of useful information.
Computational model for prediction of dangerous drug toxicity
To facilitate accurate identiﬁcation of potentially toxic drug can-
didates, we have developed a Biological Network Target-based Drug
Toxicity Risk Prediction method (TargeTox). The method aims to
leverage the guilt-by-association principle, according to which
entities close to each other in biological networks tend to share
functional roles. The distance between nodes in biological net-
works can be quantiﬁed using a variety of different methods, and
we have evaluated several strategies ranging from very simple
approaches, such as the shortest path method, to novel and ad-
vanced approaches, such as the Mashup (36) method that inte-
grates diffusion-based distances across multiple ’omics networks.
By interpreting a network as a set of pairwise distances, biological
functions and phenotypes can be associated with areas of the
network rather than just individual nodes and their location can be
efﬁciently summarized with respect to a few reference points. Once
the network location data have been put into this form and
combined with relevant covariates, a machine learning classiﬁer
was trained on the combined dataset. In principle, this strategy can
be used in combination with any modern classiﬁer that has some
form of regularization capabilities and can handle non-linear re-
lationships, for example, certain SVM variants or deep neural
networks. However, in this case, the gradient-boosted classiﬁer tree
ensemble model (GBM) was chosen for the following two reasons:
First, given the small number of positive (toxic) drugs in our training
dataset, the comparatively less hyper-parameter tuning needed by
the GBM was particularly helpful for mitigating the over-ﬁtting risk.
Second, GBM can handle the presence of missing values in our data
without the need for prior imputation, thereby greatly simplifying
both development and any possible future applications of our
method.
To control for the risk of over-ﬁtting our model, the available
data were split into a training set (80% of all drugs, Fig 4) and a
hold-out validation set (20%). The performance of different design
strategies and hyper-parameter conﬁgurations was evaluated on
the training set using ﬁve-fold cross-validation, then a model was
Figure 1. Distribution of drug-binding proteins for all drugs in “toxic” and
“safe” categories.
Counts of drugs with a particular number of bound proteins (main/off-target)
(n = 893), above—Venn diagram shows how many distinct proteins were bound by
at least one drug from each subset.
Figure 2. DSDs of the protein–protein interaction
network.
(A) Overall distribution of all pairwise DSDs for the main
connected component of the network; ﬂow chart shows
an overview of the analysis used to convert the STRING
protein–protein interaction network into a DSD matrix.
(B) Relative positions of all proteins (n = 16,610) in the
DSD space. All pairwise distances were projected into
two dimensions using the t-distributed stochastic
neighbor embedding (t-SNE) algorithm. Red circles
show all drug-binding targets and the size of the circle is
proportional to the number of different drugs targeting
that protein.
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trained on the complete training set and evaluated on the
remaining data. We evaluated the following strategies for mea-
suring network distances: shortest path, discretized shortest path
(1 if less than length 3, 0 otherwise), DSD (33), and mashup-based
method (36). Our evaluation results showed that, generally, all of
the tested measures can to some extent be used in combination
with our method. In addition, we have evaluated two other ways of
summarizing drug-binding protein information: (1) using a medoid
protein for a set of all proteins binding a particular drug and (2)
using distance to all other proteins in the network rather than
choosing a few reference proteins. The ﬁrst strategy had achieved
69.69% receiver–operator curve (ROC) AUC (Fig S2A). The second
strategy was the second-best performing of all the tested conﬁg-
urations (ROC AUC of 72.79%, Fig S2B), however at a great cost of time
needed to train the model. For the latter strategy, we also observed
that in actuality only some points were used in the trainedmodel as
GBM algorithm performs feature selection during training. Com-
pared to those, the simple shortest path version had only slightly
lower performance (Fig S2C) and the discretized shortest path
version had the lowest overall ROC AUC of 68.4% (Fig S2D). The
performance of the method variant using mashup-based distances
was better than that of the shortest path version but still lower than
that of the DSD-based approach (Fig 5A). The best strategy was to
use a small number of reference points with a DSD metric, and for
each of them take a distance to the closest protein bound by a given
drug. This method achieved ROC AUC of 73.4% on the training subset
(Fig 5B) and, at optimal trade-off point, had a sensitivity of 74.7 and a
speciﬁcity of 65.8. On hold-out test set, ROC AUC for this optimal
version was 71.30% (Fig 5C). Feature importance analysis performed
on the ﬁnal version of the model (Fig 5D) indicated that, in aggregate,
network-based features were the most important category accounting
for half of all importance, whereas functional impact (FI) was the most
important single feature. No features were discarded as a result of
feature selection performed by the algorithm during training.
Evaluation of ability to predict IT
To investigate the potential of the method to detect idiosyncrati-
cally toxic drugs, we have identiﬁed two relevant subsets. The ﬁrst
had 38 drugs from our dataset that have been speciﬁcally iden-
tiﬁed as idiosyncratically toxic in the literature. The second subset
had nine drugs associated with HLA-mediated toxicity (37). HLA-
mediated toxicity is one of the prominent and relatively well-
studied examples of IT. Therefore, we reasoned that these drugs
could be used to explore the ability of our approach to identify
potential common toxicity mechanisms for a group of drugs.
To explore the performance for the more general set of 38
idiosyncratic toxic drugs, we performed a leave-one-out cross-
validation and compared the scores of the 38 drugs with those
in the safe subset. The scores were consistently and signiﬁcantly
higher (i.e., predicted to be more toxic) for this subset (Fig 5E). Then,
we performed the same comparison for the scores from PrOCTOR
and weighted QED methods, but no signiﬁcant differences were
detected for either method (Fig S3). To explore whether our chosen
features could capture patterns speciﬁc to an idiosyncratic subset,
a more detailed feature attribution analysis was performed using
the SHAP (shapley additive explanation) value methodology for
gradient-boosted tree ensembles (38 Preprint). After computing
feature-speciﬁc SHAP values for each drug, we compared an idi-
osyncratically toxic subset with drugs where toxicity was identiﬁed
during clinical trials. For the latter subset, we veriﬁed that IT was not
reported as the main cause of clinical trial termination in the
corresponding entry of the ClinicalTrails.gov database. In addition,
Figure 3. Comparison of distances between proteins binding the same drug
and a random sample.
(A) All “toxic” and “safe” drugs versus an analogous random sample. (B) All “safe”
drugs versus a subset of the “toxic” set that were withdrawn from the market and
an analogous random sample. In both cases the signiﬁcance was computed using
Wilcoxon signed-ranks test.
Figure 4. Overall composition of the selected drugs dataset and its
partitioning for model development.
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to the best of our ability, we checked for other factors that could
bias these results, including over-representation of particular drug
classes or indications. Each pair of SHAP value distributions was
compared using Wilcoxon signed-ranks test that identiﬁed seven
signiﬁcant differences at 5%, of which one was also signiﬁcant at
the 1% level (Table 1). These results suggest that a substantial
number of features identiﬁed as particularly important for type B
versus type A toxicity are distinctive and these differences were
captured by our method design.
To explore which features were used to correctly classify drugs in
an idiosyncratically toxic subset, we compared the relative positive
SHAP score allocations toward all model features (Fig S4). The main
difference was in the greater weight placed on all of the phar-
macologic features (two plasma protein binding and three route of
administration features). FI score also had about 3% higher relative
SHAP importance, whereas importance of the network-based
feature category decreased by about 11%. There were also con-
siderable re-allocations of importance within the network category
itself, indicating that different parts of the network were important
for correct classiﬁcation of these two groups of drugs.
For another evaluation we identiﬁed nine drugs known to be
idiosyncratically toxic via a HLA-mediated mechanism. Of all the
drugs in this category, only three were already categorized as toxic
according to our chosen criteria (clinical trial failure or market
withdrawal for reasons of toxicity). One possible explanation could
be that given that this particular mechanism is well-researched,
effective strategies exist (e.g., known risk alleles, populations and
treatment regimens) to manage these risk allowing most drugs to
be used relatively safely. Similarly, leave-one-out cross-validation
(Fig 5F, left) using original safe/toxic assignment did not indicate
that these drugs were signiﬁcantly more toxic that the main “safe”
category. Next, to further explore the potential of our method to
Figure 5. Performance benchmarks and feature importance analysis.
Receiver-operator characteristic (ROC) curves for different model variants. (A) Mashup-based distance version evaluated on the training set using ﬁve-fold cross-
validation (CV) (n = 719). (B) DSD version evaluated on the training set using ﬁve-fold CV (n = 719). (C) DSD version validated on the hold-out set (n = 174). (D) Contribution of
different features to the model measured in relative feature importance. (E) Comparison of scores returned by the model for the idiosyncratically toxic (n = 38)
and safe subsets (n = 696) computed using the ﬁnal model and leave-one-out cross-validation. (F) Comparison of scores for toxic drugs linked to HLA-mediated
toxicity (n = 9) computed using leave-one-out cross-validation; “original” sub-plot shows scores if curation-based toxicity annotation was used, and “relabeled” sub-plot
shows scores when all relevant drugs are relabeled as toxic. Signiﬁcance was computed using Wilcoxon signed-ranks test.
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detect common toxicity mechanism of this group of drugs, we
conducted an additional leave-one-out validation where all nine
drugs were relabeled as “toxic”. This change caused an increase in
the predicted toxicity score for most members of the set; however,
overall, this difference was not found to be signiﬁcant at the 5%
level (Fig 5F, right).
Independent validation using side-effect annotation
A secondary validation was performed using side-effect annotation
from the OFFSIDES database (39), from which we selected drugs not
present in either the training or hold-out subsets. After pre-
processing, the validation dataset contained 339 drugs. Given the
wide scope and diversity of possible side effects, many of which are
not considered severe enough to preclude the use of a drug, we
have selected 14 toxicity-related categories commonly associated
with failed drugs, including cardiotoxicity, hepatotoxicity, and toxic
shock. Predicted scores of drugs in these subsets were compared
with a set of 120 compounds that did not have any of these
annotations (Table 2). The average score of these major toxicity-
associated categories was higher than the average of the un-
annotated set, and the difference was signiﬁcant in all individual
cases except for nephropathy toxic and mitochondrial toxicity
categories. Likewise, the overall difference of the pooled set had a
signiﬁcantly higher average score (Fig 6). These results reafﬁrm the
particular relevance of the proposed method for identiﬁcation of
high-risk drugs of these types.
Model interpretation
Although gradient-boosted tree ensemble methods are very pow-
erful and ﬂexible, the complexity of generated models makes them
challenging to interpret directly. An additional complication arising
from the chosen design of network-based features is that by itself
the individual importance of a reference protein feature may not
directly identify bound proteins associated with toxicity risk, but
rather the approximate location of the relevant proteins in the
network. In some cases, this location can only be deﬁned by a
higher order interaction of several such features. Nevertheless, this
information is captured by the model and can be recovered to
proﬁle the potential toxicity risk of different proteins.
To extract this overall “toxicity risk map” from the model, we
created a simulated dataset of single-target drugs for each of the
proteins in the “druggable genome” list from the work of (40). Most
of this set (4,019 proteins) could be mapped to the main connected
component of the STRING protein-association network. Notably, the
highest score achieved by a simulated single-target drug was 45%
lower than the top score in a real dataset, indicating that the
highest predicted toxicity risks are because of the combined effect
of multiple causal proteins. Despite this important difference,
these results could still be useful for interpreting the behavior of
the technically “black-box” model and extraction of informative
insights. Distributions of the scores assigned to these proteins by
TargeTox were visualized to check for the presence of the coher-
ent structure. Again, this was performed with the aid of t-SNE to
project the positions relative to the 12 reference points into two
Table 1. Comparative shapley additive explanation (SHAP) analysis of
model feature importance.
Feature
Average SHAP value Wilcoxon
test
P-value
Idiosyncratic
toxicity
Clinical trial
toxicity
Network-based
features
1 0.008 0.068 0.106
2 0.043 −0.006 0.065
3 0.003 −0.006 0.438
4 0.021 −0.012 0.025*
5 0.026 0.071 0.798
6 −0.004 −0.002 0.450
7 0.001 0.166 0.003**
8 −0.014 0.255 0.017*
9 0.005 −0.005 0.044*
10 0.003 0.043 0.062
11 0.058 0.009 0.019*
12 0.047 0.052 0.659
Functional diversity 0.104 0.181 0.601
Administration route
Oral 0.047 0.036 0.554
Parenteral 0.043 0.014 0.019*
Topical 0.033 0.026 0.674
Protein binding
Lower bound 0.025 0.146 0.01*
Upper bound 0.014 0.097 0.171
*P < 0.05; **P < 0.01.
Table 2. Average scores of the OFFSIDES toxicity categories compared
with 120 drugs without such annotations.
OFFSIDES side effect Counts Mean TargeTox score P-value
Cardiotoxicity 26 1.12 2.257 × 10−6
Skin toxicity 30 0.95 1.180 × 10−5
Pulmonary toxicity 38 0.69 1.425 × 10−4
Gastrointestinal toxicity 34 0.73 4.766 × 10−4
Toxic encephalopathy 46 0.40 1.249 × 10−3
Haematotoxicity 39 0.56 1.112 × 10−3
Hepatotoxicity 66 0.15 5.588 × 10−3
Ocular toxicity 12 1.04 1.891 × 10−3
Bone marrow toxicity 23 0.44 9.885 × 10−3
Toxic shock 10 0.75 0.011
Drug toxicity 120 0.11 0.011
Ototoxicity 15 0.64 0.023
Nephropathy toxic 47 −0.05 0.184
Mitochondrial toxicity 15 −0.09 0.266
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dimensions. These results (Fig 7A) showed that bound proteins
predicted to have a higher risk are concentrated in several hot
spots. The top 10% of these predictions were separately clustered to
identify possible high toxicity risk subgroups. Clustering suggested
the presence of eight subgroups (Fig 7B), four of which (1–3 and 6)
corresponded to compact and distinctive neighborhoods sug-
gested by the t-SNE algorithm and four others were distributed over
wider areas.
Common functional roles of these protein groups were identiﬁed
using functional enrichment analysis (Fisher’s exact test with false
discovery rate correction) with respect to the biological process
(BP) aspect of the Gene Ontology. Overall, the most common re-
curring processes included signaling and protein phosphorylation,
with multiple signiﬁcant hits across all clusters, with the highest
fraction in cluster 1 (94.12% of all proteins, P = 0.002). The highest
predicted toxicity risk scores were particularly concentrated in
clusters 1 through 3, which were also placed close together by the
t-SNE algorithm, suggesting similar protein–protein interaction
context. Some notable potentially relevant functions included
immune-related processes (clusters 1, 2, 5, and 6, or multiple).
Disruption of immune system processes frequently underlies toxic
side effects (41). Clusters 1 and 3 were enriched for peptidyl-
tyrosine phosphorylation (86.3% of all members, P = 4.02 × 10−30
in cluster 1 and 70% in cluster 3, P = 0.002) and, in cluster 1, also
positive regulation of JAK-STAT cascade (13.73%, P = 2.74 × 10−4).
Tyrosine kinases are prominently linked to idiosyncratic toxic side
effects, including cardiotoxicity (42), whereas the JAK-STAT pathway
is important for different aspects of neurologic toxicity (43). Cluster
5 was signiﬁcantly enriched for response to toxins (15.38%, P = 0.03).
Cluster 4 had a high number of G-protein–coupled receptor sig-
naling pathway members (60%, P = 0.01). Apoptotic process, be-
lieved to play an important role in drug-induced hepatotoxicity (44)
and cardiotoxicity (45), was the largest enriched category in cluster
7 (63.62%, P = 0.01). No signiﬁcant GO term enrichment for any
functions was identiﬁed in cluster 8. Full results of this analysis in
the form of gene annotations, their cluster assignments, and GO BP
enrichment are provided in the supplementary material (Tables S1
and S2).
In terms of individual protein ranking of the “druggable genome”
set, the highest toxicity-scoring predictions were concentrated in
clusters 1–3. Top predictions featured several proteins identiﬁed as
promising anti-cancer drug targets. The highest ranked protein with
a score of 1.77 was FGFR2, a tyrosine kinase and an important
oncogene. In particular, this protein binds the AZD4547 candidate
drug, clinical trials of which have reported a number of serious
toxicity incidents (46). The third highest scoring protein TLR4 is
suggested to play an important role in chemotherapy-induced gut
toxicity (47) and nephrotoxicity (48). Among other proteins in the
top 10 were AKT1, KIT, JAK2, and LYN. AKT1 is a serine/threonine
kinase, inhibition of which was found to be linked to liver injury and
development of hepatocellular carcinoma in animal models, with
possible implications for human clinical trials currently in progress
(49). The proteins KIT, JAK2, and LYN are all members of the tyrosine
kinase family that have many promising drug targets while also
being associated with serious toxicities, both on-target (50) and
unexpected (51), and, more speciﬁcally, idiosyncratic hepatotoxicity
(52). One notable example somewhat further down the list was
PTGS2 (COX2), which was rated in the top 2% for likely toxicity and is
the key protein target, leading to high-proﬁle withdrawal of Vioxx
drug because of the doubling of heart attack risk (53).
Discussion
One principle obstacle to the development of computational pre-
dictive approaches is the sheer complexity of the interplay between
factors that determine whether a drug is considered to have an
unacceptable level of toxicity (Fig 8). The fundamental trade-off
at the core of this decision is striking the right balance between
efﬁcacy and safety (54), both of which are evaluated with respect
to the severity of the disease to be treated. Each of these factors
may be subject to considerable variation. Only a small number of
Figure 6. Comparison of scores for annotation-based toxicity categories.
major toxic category contains all drugs with toxicity-related annotations from the
OFFSIDES database (n = 257), and the safe category contains all drugs without any
such annotations (n = 120). All drugs that were already present in a set used to
train the model were excluded. Signiﬁcance was computed using Wilcoxon
signed-ranks test.
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people might experience a toxic side effect and it may have dif-
ferent degrees of severity and, in the case of idiosyncratic re-
sponses, the exact underlying causes can be particularly complex
(55). Furthermore, extrinsic factors such as cost, availability of al-
ternative treatments, and ability to predict or manage risks also
inform the ﬁnal decision (56). Although ideally it is very desirable to
directly incorporate the effects of these factors into a predictive
toxicity model, at present such data are still not systematically
collected at the necessary level of detail. Not being able to
accurately model these effects is an important factor limiting the
accuracy of computational drug screening approaches, but struc-
tured data collection efforts by initiatives such as ClinicalTrials.gov
are likely to address this data availability problem in the near
future.
Another limitation is the actual number of failed drug obser-
vations that are currently available in the public domain. A very
large number of features may need to be included in the model to
adequately capture the underlying complexity, which in turn would
A B
Figure 7. Druggable proteome annotation with the TargeTox method.
Two panels show the druggable proteome (n = 4,019) with layout based on DSDs computed from the STRING protein association network and mapped to two
dimensions using the t-SNE method. (A) Protein nodes colored according to TargeTox score (red = highest risk, blue = lowest risk). (B) Locations of distinctive subgroups
with highest risk (top 10% of all druggable proteome by TargeTox score) with groups derived by clustering their DSD vectors.
Figure 8. Factors affecting drug safety decision-making.
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necessitate a large number of observations (example drugs) to ac-
curately proﬁle their effects. Oneway to deal with this issue could be to
mirror the drug development stages in separate steps of the com-
putational screening pipeline. In the early stages, the drug develop-
ment process primarily focuses on chemical features of screened
compounds and their pharmacokinetic features, and then biomedical
and clinical contexts are considered during laboratory and clinical
trial testing. Computational models can be specialized to achieve
optimal performance for each of these stages and combined to
form a sequential ﬁlter, for example, approaches such as QED and
ADME can be used as a ﬁrst step, then tools such as PrOCTOR to
identify compounds likely to fail during clinical trials, and lastly
methods such as ours to identify the remaining problematic
compounds. The only essential input required for TargeTox is the
identity of proteins bound by a particular drug, whereas optional
inputs, which may be missing, are the three Boolean values for
possible routes of administration and two numeric values for lower
and upper plasma protein binding. All of the other features, which
are actually used by the trained model, are computed from the
supplied list of bound proteins and the implementation released
with this article can perform this part of the analysis automatically.
Our method is particularly dependent on the knowledge of
proteins binding speciﬁc drugs, as these data are necessary to
compute both the network-based and FI features. Idiosyncratic
toxicity is often mediated by the effect on off-target proteins of
particular drugs (57). Information about all possible bound proteins
can often be incomplete, which can limit the effectiveness of the
proposed method. Some resources offer computationally derived
predictions of bound proteins (58), although use of such in-
formation would necessitate striking the right balance between
true and false positives. Another aspect not currently considered by
our model is the metabolism of the drug, which can generate toxic
secondary compounds that may result in IT and can also have their
own sets of protein interactions (59). The development of effective
strategies for incorporating this wider body of knowledge can lead
to further improvements of TargeTox and other similar methods.
Other means of making further progress could be in better
utilization of other types of biological network data. This particular
consideration was partially explored by considering distances
derived from an integrated set of networks using the mashup
method. Although in this particular case we have found that a single
network of experimentally conﬁrmed protein–protein interactions
wasmarginally better, it is very likely that the better results could be
obtained using different combinations of networks or different
edge reliability thresholds. Although we have not been able to
comprehensively explore all of these options as part of this initial
study, we believe that a more in-depth evaluation of integrative
methods such as mashup merits further investigation. In addition,
incorporation of data from cell culture proﬁling studies offered by
the Connectivity Map (60) and the more recent Library of Integrated
Network-based Cellular Signatures (61) could be another way of
more fully capturing the complexity of drug responses. The po-
tential of combining such data with network-based approaches was
recently demonstrated by the SynGeNet method (62), which suc-
cessfully predicted genotype-speciﬁc drugs for melanoma.
In this work, we were particularly interested in exploring the
problem of IT, that is, where the toxic effect is only manifested rarely
and therefore may be unnoticeable during clinical trials. We were
able to conﬁrm that the existing methods were not as effective in
identifying these drugs. We have presented an example showing that
our method can improve on the performance of existing methods
speciﬁcally for those drugs. By applying TargeTox in a speculative
way, we were also able to generate toxicity risk annotation for the
druggable proteome. This follow-up analysis suggested that bound
proteins associated with predicted toxicity risk are concentrated in
highly speciﬁc areas of the human interactome and tend to have
immune system and signaling-related functions. An additional
insight was that the highest toxicity risk scores were only predicted
by our model when a drug had several targets. This suggests that
the burden of multiple drug–protein interactions on particularly
susceptible regions of the networks could be a plausible hypothesis
for explaining most severe cases of drug toxicity.
To facilitate applications of TargeTox, we have made the trained
model, supporting data, and the necessary code available in a ded-
icated GitHub repository (https://github.com/artem-lysenko/TargeTox).
Given that the only essential input for TargeTox is the identity of bound
proteins for each drug, the method has particularly good synergy with
the currently dominant target-driven paradigm of drug development.
We believe that the method will be particularly useful for the iden-
tiﬁcation of idiosyncratically toxic drugs during a computational
screening of drug compounds and for the prior knowledge-directed
design of combinations that minimize toxicity risk.
Materials and Methods
Dataset construction
The reference dataset was based on three resources: DrugBank (63)
for drugs currently in use, ClinicalTrials.gov (64) for drugs that failed
clinical trials, and supplementary data from (4) that compiled a
comprehensive list of drugs that were withdrawn from the market
between 1950 and 2016. The latter two resources were ﬁltered
manually to only keep the drugs that have failed for toxicity-related
reasons. The DrugBank dataset was also ﬁltered to remove all an-
tineoplastic drugs, as those are expected to have relatively high
toxicity to be considered sufﬁciently similar to the “safe” drugs for
other diseases. To resolve any naming ambiguities, all drug names
were mapped to ChEMBL identiﬁers using the DrugBank database
and manual curation. Duplicates were removed to retain only one
entry, with precedence given to the “toxic” class subset. Then, the
ChEMBL database (65) was used to obtain the chemical structure
information (SMILES strings) and bound proteins (both main phar-
macological target(s) and any off-targets) for each drug. All entries
where complete informationwas not available were discarded at this
stage. This resulted in a set of 696 compounds in the “safe” category
and 197 compounds in the “toxic” category. The ChEMBL and Drug-
Bank databases were also used to obtain the pharmacological co-
variate data, speciﬁcally route of administration (oral, parenteral,
and topical) and lower and upper estimates for blood plasma protein
binding, although missing values were allowed for these features.
Data for proteins bound by each drug were integrated with a
protein association network from the STRING database (66). To
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control for false-positive edges, we only used experimentally
conﬁrmed interactions with a combined score of at least 200. To
ensure consistent distribution of distances, only the main con-
nected component of this network containing 16,610 proteins was
used for all of the analyses. Information about the biological
function of the bound proteins was acquired from the Gene On-
tology (67) annotation database and annotation of drugs with side
effects—from the OFFSIDES database (39). Additional literature
curation was performed to identify a subset of drugs with reported
IT, which is provided in supplementary materials (Table S3). Drugs
associated with HLA-mediated toxicity were identiﬁed based on the
list from (37) and are, likewise, provided in Table S4.
Computation of candidate-predictive features
Chemical structure was used to compute drug properties using the
ChemmineR package (68) applied as speciﬁed in PrOCTOR analysis
script (10). In addition, we ran all the drugs in our dataset through
PrOCTOR to obtain the PrOCTOR score and weighted QED (wQED) (9).
Several different network distance metrics were evaluated for
inclusion in our model. The simpler metrics considered were the
shortest path length in STRING protein–protein interaction graph
and the discretized shortest path where a value 1 was assigned if
the length was less than 3 and 0 otherwise. Of the more advanced
measures, we have considered mashup, which computes the dis-
tance over an integrated set of multiple biological networks, and
the DSD algorithm, a distance measure based on random walks. In
the case of Mashup, we used the pre-computedmatrix of vectors for
STRING networks made available by the authors of the algorithm.
The matrix was transformed to a distance matrix by computing the
cosine distances between all pairs of vectors. Cosine distance was
chosen because it was suggested as the most appropriate one in
the original mashup method article.
In the latter case, the network was transformed into a sym-
metrical DSD as described in the work of (33), using the following
formula:
DSDðu; vÞ =
bTu −bTvI −D−1A + P−11;
where D is the diagonal degree matrix, P is the constant matrix of
the steady-state distribution and bu, bv are the basis vectors for the
respective nodes. The DSD metric allows the ﬁne-grained mapping
of all drug-binding proteins into a network-predicated topological
space. Using this distance metric, we were able to compare the
relative distributions of different bound proteins sets. As we found
that proteins that bind to the same drug tended to be located close
to each other in the network, the position of the set can be ap-
proximated by the position of its convex hull with respect to a few
reference nodes. This transformation summarizes the biological
network location of any set of possible bound proteins in the same
small number of variables—regardless of its original size.
Next, we explored several possible designs for the network-
based features. The options considered were representing each
drug by a network-based medoid for all bound proteins of a
particular drug and using a full set of distances between closest
bound protein and each other node in the network. Given that the
latter most promising strategy had considerable computational
costs, we explored how the number of reference points could be
reduced. Speciﬁcally, the reference nodes were chosen to be the
most representative with respect to the set of all drug-binding
proteins, with the rationale being that this proximity will serve to
reduce possible noise and errors due to unavoidable missing
or spurious edges in the protein association network. Candidate
reference nodes were identiﬁed by computing enrichment for drug
binding proteins in a ﬁxed-distance neighborhood around each
node in the network (Fig 9). To reduce redundancy, all signiﬁcantly
enriched neighborhoods were clustered using hierarchical clustering
to group them into the desired number of distinctive groups. Finally,
the representative central node of the densest neighborhood in each
cluster was chosen as a reference node. Three free parameters of this
approach (neighborhood-deﬁning distance, enrichment cut-off and
number of clusters) were optimized using grid search.
FI score metric was derived from the Gene Ontology BP anno-
tations. For the purposes of this analysis annotations to each term
also inherit annotation to all of its ancestor terms. Using a complete
set of all human annotations, information content was computed
for each of the individual terms:
ICðtÞ = −ln
jktj
jkj

where t is a given GO term and k is an instance of annotation
(unique entity–term pair). Then, FI score is deﬁned as follows:
FIðTÞ =
ti2T
ICðtiÞ½descendantsðtiÞ\T = ∅;
where T is a set of all annotation terms for a set of particular drug-
binding proteins. The rationale behind the design of this feature is
Figure 9. Conceptual schematic of the network-based feature design.
All protein nodes are mapped represented by their DSD vectors (ﬁlled dots). A set
of reference nodes (c1–cn; black dots) are chosen in the areas with dense
concentration of known drug targets by computing enrichment in a ﬁxed-distance
area around each candidate node. The redundancy is then removed using
hierarchical clustering of all qualifying candidates. The network distance-based
features are deﬁned as a distance (d) between a reference node and the closest
target for a given drug (red dots).
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that a drug is expected to have an impact on some BPs as part of its
intended mechanism of action. If this impact is focused, there will
be few other processes affected, so the score will be relatively low.
On the other hand, if a drug also affects some off-target processes
or interacts with a critical protein contributing to multiple pro-
cesses, the FI score will be high. Information content serves to
achieve even further granularity of the measure, as it is low for
generic functions that are relatively common and high for spe-
cialized functions where there is little redundancy.
Classiﬁer training and evaluation
Here, we describe basic notations for training and evaluating our
proposed model. Let χ be a set of n samples in a d-dimensional
feature space which is split into a training set χtr and test set χts;
that is, χ = χtr[χts . Let Ω = fωi : i = 1; 2;…cg be the ﬁnite set of
c class labels, and ωi is the class label of ith class. To preserve the
classes, the training and test sets are subdivided into c disjoint
subsets χtr = χtr1[χtr2…[χtrc and χts = χts1[χts2…[χtsc , respectively, where
χtrj  χtr and χtsj  χts . Furthermore, it can be noted that each subset
χtrj or χtsj has class a label ωj. Let ntrj and ntsj be the number of
samples in χtrj and χtsj (of class ωj) such that
ntr = 
c
j = 1
ntrj
and
nts = 
c
j = 1
ntsj
The feature vectors of χtr and χts can be depicted as
χtr = fr1; r2;…rntrg
and
χts = fs1; s2;…; sntsg:
To perform a robust evaluation of themodel, we split up our data
into a training subset χtr and validation subset χts in ntr:nts = 80:20
ratio while preserving the ratio of the two classes in our dataset;
that is, ntr1=ntr2 ≈ nts1=nts2. During development, evaluation was
performed using a ﬁve-fold cross-validation approach using only
the compounds in the training set and the ﬁnal evaluation was
performed using the hold-out set.
To train our model, we have chosen to use a gradient-boosting
algorithm. The objective of the gradient boosting algorithm is to
ﬁnd an approximation bFðxÞ of a function F(x) such that the expected
value of a loss function Lð ̇Þ is minimum (69); that is,
bF = argminFE½Lðy; FðxÞÞ;
where y is the class label of a feature vector x, and E½ ̇ is the
expectation function. Gradient boosting is generally used with
decision trees h(x). The t-th step gradient boosting with decision
trees ht(x) is updated in Friedman’s algorithm as follows:
bFt←bFt−1 + γthtðxÞ;
where the step size γt is selected such that the loss function Lð ̇Þ is
minimized. For this work, we have used a gradient-boosting tree
classiﬁer ensemble implementation from the “catboost” v0.10.3 R
library (70 Preprint). Classiﬁer hyper-parameters and parameters of
the network feature design were tuned on the test set using grid
search, and then the optimal conﬁguration was validated on the
hold-out set and used to train the ﬁnal model. Primary evaluation
of performance was performed on the basis of area under the ROC
AUC, computed using “PRROC” R package with “toxic” class in-
stances set as the foreground class.
Feature importance analysis
Feature importance analysis was performed using implementa-
tions available in the “catboost” R library, which allows compu-
tation of canonical the decision tree ensemble importance scores
and SHAP score metrics. Importance scores were computed for the
ﬁnal model that was trained on the complete dataset (i.e., a union
of train and test subsets). The SHAP scores were computed for each
individual drug by running a leave-one-out cross-validation on an
entire set. Two types of comparisons were performed, which aimed
to proﬁle the differences between the “idiosyncratically toxic” and
“clinical trial toxic” subsets. The ﬁrst looked at the averages of all
per-feature SHAP scores and compared their distributions using
Wilcoxon signed-ranks test. The second comparison only consid-
ered feature scores that contributed to the correct classiﬁcation of
respective drugs as toxic and compared the relative totals allocated
to each feature in percentage terms.
Validation using side-effects data
Side-effects information was downloaded from the OFFSIDES da-
tabase (39). This drug annotation was combined with the STITCH
database (58) to map them to the protein association network. As
opposed to ChEMBL, which was used to construct our training
data, STITCH also includes speculative protein-binding annota-
tion. Therefore, to make these datasets comparable, only high-
conﬁdence (score > 800) annotations and proteins also present in
the protein–protein association network were retained. The drugs
were ﬁltered to remove those present in either the training or hold-
out subsets, which resulted in 339 compounds being retained. From
the set of available annotations for those drugs, we have selected
all major toxicity-associated side effects with at least 10 occur-
rences, which resulted in 14 categories. These side effects included
most categories commonly linked to drug withdrawals (4), such as
cardiotoxicity, hepatotoxicity, and nephropathy. The predicted scores
of drugs in those categories were compared with the remaining
subset which did not have any of these annotations using Wilcoxon
signed-ranks test.
Model interpretation and annotation of the druggable proteome
The overall contribution of individual features to the model was
quantiﬁed with a feature importance metric and possible rela-
tionships between individual features with an interaction strength
metric using implementations included in the “catboost” library. To
extract the overall map of toxicity risk from the model, we used a
druggable genome dataset from (40). The reasoning behind this
choice was that these drug-binding proteins are bothmost relevant
and most likely to be consistent with the data used for training. For
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each protein, a simulated parenteral drug instance was generated
using real DSD distance to the reference points and GO functional
annotation of that protein, with remaining features set to missing.
To explore possible patterns, distances of these proteins to 12
reference points were mapped onto a 2-D space using the t-SNE
algorithm with default settings. To further proﬁle areas of the
highest predicted toxicity, the top 10% of proteins by score were
analyzed as a separate set. Speciﬁcally, modules in this subset
were identiﬁed by ﬁtting a Gaussian ﬁnite mixture model using
the expectation-maximization algorithm. This analysis was per-
formed using an implementation from “pvclust” R package (71).
Then, functional enrichment test was performed for each identiﬁed
module using Fisher’s exact test followed by Benjamini–Hochberg
false discovery rate correction.
An implementation of the method and the supporting data have
been made available in a public GitHub repository with the fol-
lowing URL: https://github.com/artem-lysenko/TargeTox. All other
data used in this study were acquired from the relevant public
resources as identiﬁed in the Materials and Methods section.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201800098.
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